Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine

References

• Agid O, Kapur S, Arenovich T, Zipursky RB. 2003. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 60(12):1228–1235. doi:10.1001/archpsyc.60.12.1228
   PubMed Web of Science ®Google Scholar
• Albert N, Bertelsen M, Thorup A, Petersen L, Jeppesen P, Le Quack P, Krarup G, Jørgensen P, Nordentoft M. 2011. Predictors of recovery from psychosis: analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophrenia Res. 125(2-3):257–266. doi:10.1016/j.schres.2010.10.013
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. 2008. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin. 34(6):1163–1171. doi:10.1093/schbul/sbm134
   PubMed Web of Science ®Google Scholar
• Caccia S, Pasina L, Nobili A. 2010. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther. 4 :33–48. doi:10.2147/dddt.s6443
   PubMed Web of Science ®Google Scholar
• Chung Y-C, Cui Y, Kim M-G, Kim Y-J, Lee K-H, Chae S-W. 2016. Early predictors of a clinical response at 8 weeks in patients with first-episode psychosis treated with paliperidone ER. J Psychopharmacol. 30(8):810–818. doi:10.1177/0269881116654698
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, Vázquez-Barquero JL. 2007. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatric Res. 41(8):659–666. doi:10.1016/j.jpsychires.2006.05.002
   PubMed Web of Science ®Google Scholar
• Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS, Group ES. 2010. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol. 30(2):176–180. doi:10.1097/JCP.0b013e3181d2193c
   PubMed Web of Science ®Google Scholar
• Giegling I, Porcelli S, Balzarro B, Andrisano C, Schäfer M, Möller H-J, Rujescu D, Serretti A. 2012. Antipsychotic response in the first week predicts later efficacy. Neuropsychobiology. 66(2):100–105. doi:10.1159/000337739
   PubMed Web of Science ®Google Scholar
• Grace AA, Bunney BS. 1995. Electrophysiological properties of midbrain dopamine neurons. In: Floyd E. Bloom, David J. Kupfer, editors. Psychopharmacology,4th ed. New York: NY: Raven Press. pp. 163–177.
   Google Scholar
• Hatta K, Otachi T, Sudo Y, Hayakawa T, Ashizawa Y, Takebayashi H, Hayashi N, Hamakawa H, Ito S, Nakase R. 2011. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophrenia Research. 128(1-3):127–135. doi:10.1016/j.schres.2011.02.011
   PubMed Web of Science ®Google Scholar
• Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. 2005. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. AJP. 162(5):939–946. doi:10.1176/appi.ajp.162.5.939
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin. 13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM. 2008. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 102(1-3):230–240. doi:10.1016/j.schres.2008.02.021
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM. 2010. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacol. 35(2):581–590. doi:10.1038/npp.2009.164
   PubMed Web of Science ®Google Scholar
• Leucht S, Shamsi SAR, Busch R, Kissling W, Kane JM. 2008. Predicting antipsychotic drug response–replication and extension to six weeks in an international olanzapine study. Schizophrenia Research. 101(1-3):312–319. doi:10.1016/j.schres.2008.01.018
   PubMed Web of Science ®Google Scholar
• Marder SR, van Kammen D. 2000. Comprehensive textbook of psychiatry. Vol. 2, 7th ed. New York: Lippincott Williams and Wilkins, pp. 2356–2377.
   Google Scholar
• Rajkumar A, Chitra C, Bhuvaneshwari S, Poonkuzhali B, Kuruvilla A, Jacob K. 2011. Clinical predictors of response to clozapine in patients with treatment resistant schizophrenia. Psychopharmacol Bull. 44(3):51–65.
   PubMedGoogle Scholar
• Saravanan B, Jacob K, Johnson S, Prince M, Bhugra D, David AS. 2010. Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br J Psychiatry. 196(6):454–459. doi:10.1192/bjp.bp.109.068577
   PubMed Web of Science ®Google Scholar
• Selten J-P, Veen ND, Hoek HW, Laan W, Schols D, van der Tweel I, Feller W, Kahn RS. 2007. Early course of schizophrenia in a representative Dutch incidence cohort. Schizophrenia Research. 97(1-3):79–87. doi:10.1016/j.schres.2007.07.008
   PubMed Web of Science ®Google Scholar
• Singh A, Beniwal RP, Kukshal P, Bhatia T, Thelma B, Deshpande SN. 2018. A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia. Indian J Psychiatry. 60(1):10. doi:10.4103/psychiatry.IndianJPsychiatry_104_18
   PubMed Web of Science ®Google Scholar
• Solanki RK, Singh P, Midha A, Chugh K. 2008. Schizophrenia: impact on quality of life. Indian J Psychiatry. 50(3):181. doi:10.4103/0019-5545.43632
   PubMedGoogle Scholar
• Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J. 2011. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 187(1-2):42–48. doi:10.1016/j.psychres.2010.11.017
   PubMed Web of Science ®Google Scholar
• Thara R. 2014. Schizophrenia - Enhancing hope with better care & research. Indian J. Med. Res. 140(4):469–471.
   PubMedGoogle Scholar
• Vigo D, Thornicroft G, Atun R. 2016. Estimating the true global burden of mental illness. The Lancet Psychiatry. 3(2):171–178. doi:10.1016/S2215-0366(15)00505-2
   PubMed Web of Science ®Google Scholar
• Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L. 2001. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. AJP. 158(7):1149–1151. doi:10.1176/appi.ajp.158.7.1149
   Google Scholar
• Yildiz M, Yazici MK, Yagcioglu AEA, Karahan S, Sevik AE, Gurses N. 2015. Prediction of Response to Antipsychotic Drugs in Schizophrenia Patients within the Early Phase of Treatment. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 25(4):390–398. doi:10.5455/bcp.20151128021707
   Web of Science ®Google Scholar
• Zhang H-X, Shen X-L, Zhou H, Yang X-M, Wang H-F, Jiang K-D. 2014. Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai. Psychiatry Res. 215(1):20–25. doi:10.1016/j.psychres.2013.10.022
   PubMed Web of Science ®Google Scholar